ACEI联合ARB治疗儿童慢性肾脏疾病的疗效分析

The effect and safety of ACEI combined with ARB in treatment of chronic kidney disease

目的研究ACEI联合ARB应用于儿童慢性肾脏疾病的疗效及安全性。方法选取2012年5月2015年6月期间我院收治的80例慢性肾脏疾病的患儿作为研究对象,将所有患者随机分为三组:其中A组26例(卡托普利0.5mg/kg/d),B组27例(卡托普利1.0mg/kg/d),C组27例(卡托普利0.5mg/kg/d+氯沙坦0.8mg/kg/d)。比较各组患者的治疗有效率、不良反应发生率、治疗前后的血压及尿蛋白变化。结果A组有效率76.92%,不良反应发生率11.54%;B组有效率88.89%,不良反应发生率25.93%;C组有效率100.00%,不良反应发生率14.81%,差异具有统计学意义(P<0.05)。各组患儿治疗后的SBP和24h蛋白尿量的差异具有统计学意义(P<0.05),DBP差异无统计学意义(P>0.05)。结论 ACEI联合ARB应用于儿童慢性肾脏疾病的疗效较为明显且安全性较为可靠。

Objective To study the effect and safety of ACEI combined with ARB in the treatment of chronic kidney disease.Methods From May 2012 to June 2015,80 patients were chosen as study objects.All patients were randomly divided into 3groups：26patients in group A（captopril 0.5mg/kg/d）;27patients in group B（captopril 1.0mg/kg/d）and 27 patients in group C（captopril 0.5mg/kg/d＋losartan 0.8mg/kg/d）.The effect rate and rate of side reactions were compared among three groups,and the SBP,DBP and 24 hurinary protein were compared.Results In group A,the effect rate was 76.92%,the rate of side reaction was 11.54%%.In group B,the effect rate was 88.89%,the rate of side reaction was 25.93%.In group C,the effect rate was 100.00%,the rate of side reaction was 14.81%.The difference had statistical significance（P〈0.05）.After treatment,SBP and 24 hurinary protein had statistical difference among three groups（P〈0.05）,and the difference of DBP had no statistical difference among three groups（P〉0.05）.Conclusion ACEI combined with ARB has significant effect on treatment of chronic kidney disease,and the safety is reliable.